411 results on '"Ossenkoppele, G J"'
Search Results
2. Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome
3. Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality
4. Measurable residual disease testing in acute myeloid leukaemia
5. Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
6. The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system
7. MicroRNA-551b is highly expressed in hematopoietic stem cells and a biomarker for relapse and poor prognosis in acute myeloid leukemia
8. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia
9. A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia
10. Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989–2012
11. Factors that influence treatment decision-making in elderly DLBCL patients: a case vignette study
12. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center
13. Allogeneic transplantation after reduced-intensity conditioning with fludarabine–CY for both indolent and aggressive lymphoid malignancies
14. Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
15. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results
16. Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib
17. Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40
18. Auto-SCT in refractory celiac disease type II patients unresponsive to cladribine therapy
19. Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification
20. Supplement to: High-dose daunorubicin in older patients with acute myeloid leukemia.
21. Aberrant marker expression patterns on the CD34+CD38− stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission
22. High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study
23. Flt-3 internal tandem duplication hampers differentiation of AML blasts towards leukemic dendritic cells
24. Maintained immunogenicity of chronic myeloid leukemia-derived dendritic cells in the presence of Imatinib mesylate: implication for vaccination regimens
25. Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma
26. Identification of genes potentially involved in disease transformation of CML
27. Gene expression profiling of minimal residual disease in acute myeloid leukaemia by novel multiplex-PCR-based method
28. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia
29. TNF-α receptor 1 expression on acute myeloid leukemic blasts predicts differentiation into leukemic dendritic cells
30. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas
31. Minimal residual disease in acute myeloid leukemia is predicted by P-glycoprotein activity but not by multidrug resistance protein activity at diagnosis
32. A flow cytometric method to detect apoptosis-related protein expression in minimal residual disease in acute myeloid leukemia
33. High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome
34. Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia
35. Nilotinib in patients with Ph + chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results
36. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia: A study of 6,515 cases of AML: V27
37. How to discriminate leukemic and normal stem cells in AML and CML: V45
38. Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas
39. Outcome of ICU treatment in invasive aspergillosis
40. Leukemia-derived dendritic cells in acute myeloid leukemia exhibit potent migratory capacity
41. Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphomas
42. Minimal residual disease cells in AML patients have an apoptosis-sensitive protein profile
43. Leukaemic dendritic cell vaccination for patients with acute myeloid leukaemia
44. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma
45. Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells
46. Acute lymphoblastic leukaemia in adults: Immunological subtypes and clinical features at presentation
47. Long term effects of vincristine on the peripheral nervous system
48. Health related quality of life in patients with multiple myeloma undergoing a double transplantation
49. Differences of cellular composition and adhesion molecule expression in “leukemic” as compared with “normal” human long-term bone marrow cultures
50. Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.